Morgan Stanley analyst Aisyah Noor initiated coverage of Tecan with an Equal Weight rating and CHF 300 price target. The analyst says near-term earnings risk from a still-volatile life sciences end market clouds the company’s longer term secular growth narratives around rising lab automation and genomic testing adoption.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TCHBF: